Key Takeaways PFE's non-COVID revenues are rising, fueled by new drugs, key in-line products and Seagen acquisition. The Seagen deal added four ADCs to PFE's oncology portfolio, boosting revenues in 2024 and early 2025. PFE shares trade at a forward P/E of 7.97, well below the industry average and its 5-year historical mean.With the end of the pandemic, sales of Pfizer’s (PFE) COVID products, Comirnaty and Paxlovid, have declined. Though COVID revenues are declining, Pfizer’s non-COVID operational revenue ...

Key Takeaways PFE stock is down 10.7% YTD, underperforming its industry, sector, and the broader market. COVID product sales are falling, but oncology drugs and Seagen assets are boosting top-line growth. PFE trades well below peers in terms of valuation and offers a 7.4% dividend yield with rising EPS estimates.Pfizer’s (PFE) stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also underperformed the sector and the S&P 500, as seen in the chart below ...

Pfizer Inc. (NYSE:PFE) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 8:00 AM ET Company Participants Albert Bourla - Chairman of the Board & CEO Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Asad Haider Great. Good morning, everyone, and welcome to our 46th Annual Global Healthcare Conference. My name is Asad Haider, I'm the U.S. pharma analyst here at Goldman Sachs and we are very privileged to have Albert Bourla with us to kick off this confe ...

Pfizer (PFE) FY Conference June 09, 2025 08:00 AM ET Speaker0 Great. Good morning, everyone, and welcome to our forty sixth Annual Global Healthcare Conference. My name is Assad Heather. I'm The U. S. Pharma Analyst here at Goldman Sachs. And we are very privileged to have Albert Bula with us to kick up this conference. Albert's the CEO of Pfizer. Albert, thank you for being with us. Speaker1 Great pleasure. Speaker0 Albert, we have about thirty five minutes, so I wanna start with a big picture question for ...

辉瑞公司CEO：在最惠国条款下，公司可能会重新考虑在欧洲的药物上市策略。 ...

If you have an opening in your portfolio for a great stock with solid growth potential and perhaps even a respectable dividend yield, you would do well to give Pfizer (PFE 1.04%) some serious consideration.As with any stock, there are very good reasons to consider buying into Pfizer and also some reasons to take a more cautious stance. Here's a look at some reasons why you might buy -- or not buy -- shares of Pfizer. Pfizer: An introductionWith a recent market value near $133 billion, Pfizer is a pharmaceut ...

Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Should you chase high yields from slow-growing businesses or invest in lower-yield providers with more predictable cash flows?Lately, Pfizer (PFE 0.17%) and Prologis (PLD -0.52%) have been perfect examples of the trade-off between attractive yields and dividend growth. Pfizer offers a sky-high yield that's climbing slowly. Prologis offers a much lower yield, but it's been raising its payout at a remarkable pace.H ...

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...

CANADA - 2025/04/03: In this photo illustration, the Pfizer logo is seen displayed on a smartphone ... More screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a late-stage trial, and concerns about management’s decisions on R&D spending and ac ...

公司业绩表现 - 公司股价自2022年以来下跌56% [1] - 2024年总收入为636亿美元，同比增长7%，其中新冠产品贡献111亿美元 [2][3] - 剔除新冠产品后收入同比增长12% [3] - 美国市场新冠疫苗收入20.04亿美元，占该产品全球收入的37% [7] 新冠业务影响 - 新冠疫苗Comirnaty和药物Paxlovid曾是收入支柱，但销售额已大幅下滑 [2] - FDA新规将新冠疫苗接种建议范围缩小至65岁以上及高风险人群，秋季生效 [5][6] - 新规可能降低疫苗接种率但增加Paxlovid处方量 [7] 研发管线进展 - 以12.5亿美元首付款+48亿美元潜在里程碑付款引进抗癌药SSGJ-707 [10] - 公司在肿瘤学领域拥有丰富管线及开发经验，预计将取得重大监管突破 [11] - 计划持续削减成本至2027年 [11] 未来展望 - 2025年收入指引中位数为625亿美元，略低于2024年水平 [8] - 公司复苏更可能依赖肿瘤学等非新冠领域而非疫苗业务 [9][11] - 早期在新冠市场的成功掩盖了管线投资效果，长期仍具潜力 [12]